275 related articles for article (PubMed ID: 23403634)
1. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
[TBL] [Abstract][Full Text] [Related]
2. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
3. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C
Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358
[TBL] [Abstract][Full Text] [Related]
4. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
[TBL] [Abstract][Full Text] [Related]
5. SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.
Eytan DF; Snow GE; Carlson S; Derakhshan A; Saleh A; Schiltz S; Cheng H; Mohan S; Cornelius S; Coupar J; Sowers AL; Hernandez L; Mitchell JB; Annunziata CM; Chen Z; Van Waes C
Cancer Res; 2016 Sep; 76(18):5442-5454. PubMed ID: 27469115
[TBL] [Abstract][Full Text] [Related]
6. SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.
Ding J; Qin D; Zhang Y; Li Q; Li Y; Li J
Mol Med Rep; 2020 Mar; 21(3):1251-1257. PubMed ID: 31922244
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
[TBL] [Abstract][Full Text] [Related]
8. SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.
Greer RM; Peyton M; Larsen JE; Girard L; Xie Y; Gazdar AF; Harran P; Wang L; Brekken RA; Wang X; Minna JD
Cancer Res; 2011 Dec; 71(24):7640-8. PubMed ID: 22049529
[TBL] [Abstract][Full Text] [Related]
9. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
Carter BZ; Mak PY; Mak DH; Shi Y; Qiu Y; Bogenberger JM; Mu H; Tibes R; Yao H; Coombes KR; Jacamo RO; McQueen T; Kornblau SM; Andreeff M
J Natl Cancer Inst; 2014 Feb; 106(2):djt440. PubMed ID: 24526787
[TBL] [Abstract][Full Text] [Related]
10. The SMAC mimetic birinapant attenuates lipopolysaccharide-induced liver injury by inhibiting the tumor necrosis factor receptor-associated factor 3 degradation in Kupffer cells.
Liu H; Liao R; He K; Zhu X; Li P; Gong J
Immunol Lett; 2017 May; 185():79-83. PubMed ID: 28286228
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.
Welsh K; Milutinovic S; Ardecky RJ; Gonzalez-Lopez M; Ganji SR; Teriete P; Finlay D; Riedl S; Matsuzawa S; Pinilla C; Houghten R; Vuori K; Reed JC; Cosford ND
PLoS One; 2016; 11(9):e0161952. PubMed ID: 27617834
[TBL] [Abstract][Full Text] [Related]
12. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.
Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX
Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
[TBL] [Abstract][Full Text] [Related]
14. Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.
Srivastava AK; Jaganathan S; Stephen L; Hollingshead MG; Layhee A; Damour E; Govindharajulu JP; Donohue J; Esposito D; Mapes JP; Kinders RJ; Takebe N; Tomaszewski JE; Kummar S; Doroshow JH; Parchment RE
Clin Cancer Res; 2016 Feb; 22(4):1000-10. PubMed ID: 26446940
[TBL] [Abstract][Full Text] [Related]
15. USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics.
Lee EW; Seong D; Seo J; Jeong M; Lee HK; Song J
Cell Death Differ; 2015 Sep; 22(9):1463-76. PubMed ID: 25613375
[TBL] [Abstract][Full Text] [Related]
16. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
Bockbrader KM; Tan M; Sun Y
Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
[TBL] [Abstract][Full Text] [Related]
17. SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma Multiforme.
Cerna D; Lim B; Adelabu Y; Yoo S; Carter D; Fahim A; Mitsuuchi Y; Teicher BA; Bernhard E; Coleman CN; Takebe N; Ahmed MM
Radiat Res; 2021 Jun; 195(6):549-560. PubMed ID: 33826739
[TBL] [Abstract][Full Text] [Related]
18. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL.
McComb S; Aguadé-Gorgorió J; Harder L; Marovca B; Cario G; Eckert C; Schrappe M; Stanulla M; von Stackelberg A; Bourquin JP; Bornhauser BC
Sci Transl Med; 2016 May; 8(339):339ra70. PubMed ID: 27194728
[TBL] [Abstract][Full Text] [Related]
19. Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death.
Vetma V; Rožanc J; Charles EM; Hellwig CT; Alexopoulos LG; Rehm M
Oncol Res; 2017 Nov; 25(9):1489-1494. PubMed ID: 28337955
[TBL] [Abstract][Full Text] [Related]
20. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.
Condon SM; Mitsuuchi Y; Deng Y; LaPorte MG; Rippin SR; Haimowitz T; Alexander MD; Kumar PT; Hendi MS; Lee YH; Benetatos CA; Yu G; Kapoor GS; Neiman E; Seipel ME; Burns JM; Graham MA; McKinlay MA; Li X; Wang J; Shi Y; Feltham R; Bettjeman B; Cumming MH; Vince JE; Khan N; Silke J; Day CL; Chunduru SK
J Med Chem; 2014 May; 57(9):3666-77. PubMed ID: 24684347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
